Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVM

Alternate Symbol(s):  PAVMZ

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS

PR Newswire April 19, 2023

Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference

PR Newswire April 17, 2023

Lucid Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection of Esophageal Precancer and Cancer

PR Newswire March 31, 2023

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2022 Financial Results

PR Newswire March 14, 2023

/C O R R E C T I O N -- Lucid Diagnostics/

PR Newswire March 14, 2023

Lucid Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results

PR Newswire March 13, 2023

PAVmed to Hold a Business Update Conference Call and Webcast on March 15, 2023

PR Newswire March 3, 2023

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 14, 2023

PR Newswire March 3, 2023

PAVmed Digital Health Subsidiary Veris Health's Veris Cancer Care Platform(TM) Goes Live

PR Newswire February 28, 2023

Lucid Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event

PR Newswire February 15, 2023

PAVmed and Lucid Diagnostics Provide Strategic Business Update

Business Wire January 17, 2023

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

Business Wire January 11, 2023

PAVmed Partners with Novosound on Ultrasound Imaging Technology

Business Wire December 22, 2022

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

Business Wire December 15, 2022

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

Business Wire December 8, 2022

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Business Wire December 1, 2022

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

Business Wire November 15, 2022

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

Business Wire November 14, 2022

PAVmed to Participate in BTIG Digital Health Forum

Business Wire November 11, 2022

Lucid Diagnostics to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Business Wire November 10, 2022